Právní předpis byl sestaven k datu 19.12.2013.
Zobrazené znění právního předpisu je účinné od 25.12.2012 do 19.12.2013.
97
XXXXXXX
Xxxxxxxxxxxx xxxxxxxxxxxx xxxx,
xxxxxx xx mění x xxxxxxxx xxxxxxx Xxxxxxxxxxxx zahraničních xxxx x. 58/2007 Sb. x. x., x. 46/2008 Xx. m. x. a x. 47/2012 Xx. x. x. o Mezinárodní xxxxxx xxxxx dopingu xx xxxxxx
Xxxxxxxxxxxx zahraničních xxxx xxxxxxx, že dne 16. xxxxxxxxx 2011 xxxx xxxxxxxxx xxxxxxxxxx XXXXXX xxxxxxxx schválení xxxxxx xxxxx Xxxxxxx X - Xxxxxxx xxxxxxxxxx látek x xxxxx - Xxxxxxxxxxx xxxxxxxx Mezinárodní úmluvy xxxxx xxxxxxx xx xxxxxx.1)
X xxxxx xxxxxx Xxxxxxx I xxxxxxxx souhlas Parlament Xxxxx republiky.
Xxxx xxxxx Xxxxxxx X xxxxxxxxx x xxxxxxxx x xxxxxxx x xxxxxxx 34 xxxx. 3 Úmluvy xxx 1. xxxxx 2012 x xxxxx xxxx xxxxxxxxx x xxxxxxxx x pro Xxxxxx xxxxxxxxx. Xxxx vstupu xxxxxx xxxxx Xxxxxxx X x xxxxxxxx xxxxxxxx xxxxxx xxxxx Xxxxxxx X Mezinárodní xxxxxx xxxxx dopingu xx xxxxxx platné xx 1. xxxxx 2011 x vyhlášené xxx č. 47/2012 Sb. m. s.
Anglické xxxxx Přílohy X x její překlad xx xxxxxxx jazyka xx xxxxxxxxx xxxxxxxx.
1) Mezinárodní xxxxxx xxxxx xxxxxxx xx sportu xxxxxxx xxx 19. xxxxx 2005 x Xxxxxx xxxx xxxxxxxxx xxx č. 58/2007 Sb. m. s.
XXXXXXXXXXX XXXXXX XXXXX XXXXXXX XX XXXXXX
Xxxxxxx X - Seznam xxxxxxxxxx látek x xxxxx - Xxxxxxxxxxx xxxxxxxx
Xxxxx, 1. xxxxx 2012
XXXXXX XXXXXXXXXX LÁTEK X XXXXX DOPINGU XXX XXX 2012
XXXXXXX XXXXXXXXXXXXX XXXXX
Xxxxxx xx 1. ledna 2012
Xxxxx článku 4.2.2 Xxxxxxxxx xxxxxxxxxxxxxxx xxxxxx všechny Xxxxxxxx xxxxx budou považovány xx "Xxxxxxxxxx xxxxx" xxxxx látek xx xxxxxx X1, S2, X4.4, S4.5 x X6(x) x Zakázaných xxxxx X1, M2 x M3.
XXXXX X XXXXXX ZAKÁZANÉ XXXXX (PŘI XXXXXXX X XXXX XXXXXX) |
XXXXXXXX XXXXX
X0. XXXXXXXXXXX XXXXX
Xxxxxxxxx xxxxxxxxxxxxx xxxxx, která xxxx zahrnuta x xxxxxxxxxxxxx sekcích Xxxxxxx x není xxxxxxxx xxxxxxxxx xxx xxxxxxx xxxxxxxxxxxx použití xxxxxxxxxx xxxxxxx zdravotnickým xxxxxxxxxx xxxxxx (xxxx. xxxxxx x xxxxxxxxxxxx xxxx xxxxxxxxx stadiu xxxxxxx xxxx xx xxxxxxxx xxxxxxxxxx, xxxxxxxxxx xxxxx, xxxxxxxxxxx xxxx), xx xxxxxxxx xxxxx.
S1. XXXXXXXXXX LÁTKY
Xxxxxxxxxx xxxxx xxxx xxxxxxxx.
1. XXXXXXXXXX ANABOLICKÉ XXXXXXXX (XXX):
(x) Xxxxxxxx* XXX, xxxxxxxxxx:
1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3β,17β-xxxx); 1-xxxxxxxxxxxxx (5α-xxxxxxx-1-xx-3,17-xxxx); xxxxxxxxx (estr-4-en-3β,17β-diol); xxxxxxxxxx; xxxxxxxx; xxxxxxx (xxxxxxxx-1,4-xxxx-3,17-xxxx); danazol (17α-ethynyl-17β-hydroxyandrost-4-eno[2,3-d]isoxazol); xxxxxxxxxxxxxxxxxxxxxxxxxxxxx (4-xxxxxx-17β-xxxxxxx-17α-xxxxxxxxxxxxxx-1,4-xxxx-3-xx); xxxxxxxxxxxxxxxxxxxxxxx (17α-xxxxxx-5α-xxxxxxx-2-xx-17β-xx); xxxxxxxxxxx; xxxxxxxxxxxxx (19-xxx-17α-xxxxx-4-xx-17-xx); xxxxxxxxxxxxxx; xxxxxxxxxx; xxxxxxxxx (17β-xxxxxxx-17α-xxxxxx-5α-xxxxxxxxxx[2,3-x]-xxxxxxx); xxxxxxxxx; 4-xxxxxxxxxxxxxxxxxx (4,17β-xxxxxxxxxxxxxxxx-4-xx-3-xx); kalusteron; xxxxxxxxx; xxxxxxxxxx; xxxxxxxxxx; xxxxxxxxxxx (17β-hydroxy-17α-methylandrosta-1,4-dien-3-on); xxxxxxxxx; xxxxxxxxxxx; xxxxxxxxxx (2α, 17α-xxxxxxxx-5α-xxxxxxxxx-3-xx-17β-xx); xxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9-xxxx-3-xx); xxxxxx-1-xxxxxxxxxxx (17β-hydroxy-17α-methyl-5α-androst-1-en-3-on); xxxxxxxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxx-4-xx-3-xx); xxxxxxxxxxxxxxxxx; xxxxxxxxxx (xxxxxxxxxxxxxxx (17β-xxxxxxx-17α-xxxxxxxxxxx-4,9,11-xxxxx-3-xx); miboleron; xxxxxxxxx; 19-xxxxxxxxxxxxxxxx (xxxx-4-xx-3,17-xxxx); xxxxxxxxxx; xxxxxxxxxxxxxx; xxxxxxxxxxxx; xxxxxxxx; oxandrolon; xxxxxxxxxxx; xxxxxxxxxx; prostanozol (17β-xxxxxxx-5α-xxxxxxxxxx [3,2-x]xxxxxxx); xxxxxxxxx; xxxxxxxxxx; xxxxxxxxx; 1-xxxxxxxxxxx (17β-xxxxxxx-5α-xxxxxxx-1-xx-3-xx); xxxxxxxxxxxxxxxxxxx (18α-xxxx-xxxxxx-4,9,11-xxxxx-17β-xx-3-xx); trenbolon x další xxxxx x podobnou chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
(x) Xxxxxxxxx** XXX, xxxxx xxxx xxxxxx xxxxxxxx:
Xxxxxxxxxxxxx (xxxxxxx-5-xx-3β,17β-xxxx), androstendion (xxxxxxx-4-xx-3,17-xxxx), xxxxxxxxxxxxxxxxxx, xxxxxxxxx (xxxxxxxxxxxxxxxxxxxxx, XXXX), xxxxxxxxxxx x xxxxxx metabolity x isomery, xxx xx x xxxxxxxx xxxxx xx xx:
5α-xxxxxxxxx-3α,17α-xxxx | 5-xxxxxxxxxxxxx (xxxxxxx-5-xx-3,17-xxxx) |
5α-xxxxxxxxx-3α,17β-xxxx | |
5α-androstan-3β,17α-diol | xxx-xxxxxxxxxxxxxxxxxx |
5α-xxxxxxxxx-3β,17β-xxxx | epitestosteron |
xxxxxxx-4-xx-3α,17α-xxxx | 3α-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-4-xx-3α,17β-xxxx | 3β-xxxxxxx-5αxxxxxxxxx-17-xx |
xxxxxxx-5-xx-3β,17α-xxxx | 7α-hydroxy-DHEA |
xxxxxxx-5-xx-3α,17α-xxxx | 7β-xxxxxxx-XXXX |
androst-5-en-3α,17β-dioI | 7-xxxx-XXXX |
androst-5-en-3β,17α-diol | 19-xxxxxxxxxxxxxx |
4-xxxxxxxxxxxxx (xxxxxxx-4-xx-3β,17β-xxxx) | 19-xxxxxxxxxxxxxxxxx |
2. Ostatní xxxxxxxxxx xxxxx, xxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxx, xxxxxxx, zilpaterol, xxx xx x xxxxxxxx xxxxx xx xx.
Xxx xxxxx xxxxxxx xxxx xxxxx: * "xxxxxxxx" xx vztahuje x xxxxx, kterou xxxx není normálně xxxxxxx xxxxxxxxxx přirozeně. ** "xxxxxxxxx " xx xxxxxxxx x xxxxx, kterou může xxxx xxxxxxxxxx xxxxxxxxx. |
X2. XXXXXXXXX XXXXXXX, XXXXXXX XXXXXXX X PŘÍBUZNÉ LÁTKY
Xxxxxxxxxxx látky x xxxxxx uvolňující faktory xxxx xxxxxxxx:
1. Xxxxx stimulující xxxxxxxxxxx (xxxx. erytropoetin (XXX), xxxxxxxxxxx (xXXX), xxxxxxxxxxxxx xxxxxxx xxxxxxxxxxxxxx xxxxxxx (XXX), methoxypolyethylenglykol-epoetin xxxx (XXXX), xxxxxxxxxxx /Hematide/);
2. Xxxxxxxxxxxxxxxxxx (XX) x Xxxxxxxxxxxx xxxxxx (XX) x xxxx;
3. Insuliny;
4. Xxxxxxxxxxxxxx;
5. Xxxxxxx xxxxxx (XX), xxxxxxxxxxxxx xxxxxxx xxxxxxx (XXXx), xxxxxxxxxxxx xxxxxxx faktor (XXX), insulinu xxxxxxx xxxxxxx xxxxxx-1 (IGF-1), xxxxxxxxxx xxxxxxx xxxxxxx (XXX), xxxxxxx faktor xxxxxxxx x xxxxxxxx xxxxxxxx (XXXX) a xxxxxxxxxx-xxxxxxxxxxxx xxxxxxx xxxxxx (XXXX), xxxxxx xxxx xxxxxxxxx xxxx xxxxxxx xxxxxxx xxxxxxxxxxx xxxxxxx xxxx xxxxxxxxx bílkovin xxxxx, šlach x xxxxxx, krevní xxxxxxxx, xxxxxxx xxxxxxx, xxxxxxxxxxxxx xxxxxxxx xxxx ovlivňující xxxx xxxxxxxxx xxxxxx;
x další látky x xxxxxxxx chemickou xxxxxxxxxx xxxx podobnými xxxxxxxxxxxx xxxxxx.
X3. XXXX2- AGONISTÉ
Xxxxxxx xxxx-2 agonisté (xxxxxx xxxx případných xxxxxxxxx xxxxxxx) xxxx xxxxxxxx xxxxx xxxxxxxxxxx (xxxxxxxxx 1600 xxxxxxxxxx za 24 hodin), xxxxxxxxxxx (xxxxxxxxx 36 mikrogramů xx 24 hodin) x salmeterolu pokud xxxx xxxxxx x xxxxxxxx x xxxxxxx x xxxxxxxxxxx xxxxxxxx xxxxxxx xxxxxxx.
Xxxxxxxxxx xxxxxxxxxxx x xxxx x xxxxxxxxxxx vyšší xxx 1000 ng/ml x xxxxxxxxxx formoterolu x xxxx x xxxxxxxxxxx vyšší xxx 30 ng/ml xxxxxx xxxxxxxxxx xx zamýšlené xxxxxxxxxxxx xxxxxxx, xxx xxxx považována xx xxxxxxxxx xxxxxxxxxxx xxxxx, xxxxx xxxxxxxxx neprokáže xxxxxxxxxxxxx farmakokinetickou studií, xx abnormální výsledek xxx způsoben užíváním xxxxxxxxxxxx xxxxxxxxx dávky xxxxx xxx xxxx xxxxxxx xxxxxxx.
S4. XXXXXXXXX A METABOLICKÉ XXXXXXXXXX
Zakázané je xxxxxxxxxxx:
1. Xxxxxxxxxx xxxxxxxx, xxxxxxxxxx:
Xxxxxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxx-1,4,6-xxxxx-3-17-xxxx (androstatriendion), 4-xxxxxxxxx-3,6,17-xxxxx (6-xxx),xxxxxxxxx, formestan, xxxxxxxx, testolacton, xxx xx s omezením xxxxx na xx.
2. Xxxxxxxxxx xxxxxxxxxx xxxxxxxxxxxxx xxxxxxxxx (XXXX), xxxxxxxxxx:
Xxxxxxxxx, tamoxifen, xxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
3. Xxxxxxx xxxxxxxxxxxxxx látky xxxxxxxxxx:
Xxxxxxxxxx, fulvestrant, xxxxxxxx, ale xx x xxxxxxxx xxxxx xx xx.
4. Xxxxx xxxxxxxxxxxx xxxxxx xxxxxxxxxx xxxxxx inhibitorů xxxxxxxxxx, xxx xx x xxxxxxxx xxxxx xx xx.
5. Xxxxxxxxxxx xxxxxxxxxx: Xxxxxxxx xxxxx xxxxxxxxxx xxxxxxxxxxxxxx xxxxxxxxxxxxx /Xxxxxxxxxx Xxxxxxxxxxxx Xxxxxxxxx Receptor δ (PPARδ) xxxxxxxx/ (xxxx. XX 1516) x Xxxxxxxx proteinkinasové xxx xxxxxxxxxx XXX x xxxxxxxxxxx x XXXX xxxxx /XXXXδ-XXX-xxxxxxxxx xxxxxxx kinase (AMPK) xxxx xxxxxxxx/ (xxxx. XXXXX)
X5. XXXXXXXXX X XXXXXXX MASKOVACÍ XXXXX
Xxxxxxxxx látky xxxx xxxxxxxx. Zahrnují:
Xxxxxxxxx, desmopressin, xxxxxxxxxxxxxxx (xxxx. glycerol, nitrožilní xxxxxx albuminu, xxxxxxxx, xxxxxxxxxxxxxxxxxx x mannitolu), xxxxxxxxxx x další xxxxx x podobnými xxxxxxxxxxxx xxxxxx. Xxxxxxx xxxxxxxx xxxxxxxxxxxx xxx xxxxx xxxxxxxx není xxxxxxxx.
Diuretika xxxxxxxx:
Xxxxxxxxxxxx, amilorid, xxxxxxxxx, xxxxxxxxx, chlortalidon, indapamid, xxxxxxxx, kyselina etakrynová, xxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxx (xxxx. bendroflumethiazid, hydrochlorothiazid, xxxxxxxxxxxxx), triamteren a xxxxx xxxxx x xxxxxxxx chemickou xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx (xxxxx xxxxxxxxxxxx, xxxxxxxxx a xxxxxxxxx xxxxxx xxxxxxxxxxx a xxxxxxxxxxxx, xxxxx xxxxxx xxxxxxxx).
Xxx použití (Xxx Xxxxxxx, xxxxxxxx Xxxx Soutěž) xxxxxxxxxxx xxxxxxxx xxxxx se xxxxxxxxxx xxxxxxxx limitem (xx. formoterol, xxxxxxxxxx, xxxxxx, xxxxx, efedrin, xxxxxxxxxxxx a xxxxxxxxxxxxx) xx xxxxxxx x xxxxxxxxxx nebo xxxxx xxxxxxxxx xxxxxx xx xxxxxxxxxx xxxxxxx specifické Xxxxxxxxxxxx xxxxxxx na xxxx xxxxx navíc x xx, xxxxx xxx xxxx udělena xx xxxxxxxxxx xxxx xxxxx maskovací látku.
XXXXXXXX XXXXXX
X1. XXXXXXXXX XXXXXXX XXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxx xxxxxx, xxxxxx xxxxxxx xxxxxxxxx, xxxxxxxxx xxxx heterologní xxxx xxxx červených xxxxxxx x jim xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxxx.
2. Umělé xxxxxxxxx xxxxxxxx, xxxxxxx xxxx xxxxxxx kyslíku, xxxxxxxxxx xxxxxxxxxxxx xxxxxxxxxxxxx xxxxxxxx (xxxx.xxxxxx náhražky xxxxxxxx xx xxxxxxxxxxx, xxxxxxxxxxxxxxxxxx xxxxxxxxxxx), xxxxxxxxxxxxxxxxxxx x xxxxxxxxxxx (RSR13), xxx ne x xxxxxxxx xxxxx na xx. Xxxxxxxx xxxxxxx xxxxxxxx není.
X2. XXXXXXXX X XXXXXXXXX XXXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
1. Xxxxxxxxx, xxxx xxxxx x xxxxxx, za xxxxxx xxxxxxx integritu a xxxxxxxx Xxxxxx xxxxxxxxxx xxx Dopingové xxxxxxxx xx zakázané. Xx xxxxxxxx xxxxxx a/nebo xxxxxx (xxxx. proteázami) xxxx, xxx xx x xxxxxxxx xxxxx xx ně.
2. Xxxxxxxxxx xxxxxx x/xxxx xxxxxxx více xxx 50 ml za 6 hodin jsou xxxxxxxx kromě xxxxxx xxxxxxxxx přijatých v xxxxxxx xxxxxxxxxxxx xxxxxxx xxxx xxxxxxxxxx vyšetřovacích xxxxx.
3. Xxxxxxxx xxxxx, xxxxxxxxxx x xxxxxxxxx xxxxxxxxxxx xxxxxxxx xxxx krve xx xxxxxxxxx xxxxxxx je xxxxxxxx.
X3. GENOVÝ XXXXXX
X důvodu xxxxxxxxxx ke xxxxxxx xxxxxxxxxxx xxxxxx je xxxxxxxx xxxxxxxxxxx:
1. Xxxxxxxx xxxxxxxxxx xxxxxxx xxxx xxxxxx sekvencí;
2. Použití xxxxxxxxxx xxxx xxxxxxxxx modifikovaných xxxxx;
XXXXX X XXXXXX ZAKÁZANÉ XXX XXXXXXX |
Xxxxx xxxxxxxxx SO xx S5 a X1 xx X3 xxxxxxxxx xxxx xxxx Xxx Xxxxxxx xxxxxxxx x následující xxxxxxx:
XXXXXXXX XXXXX
S6. XXXXXXXXXXX
Všechna stimulancia (xxxxxx xxxx xxxxxx xxxxxxxxxx xxxxxxxxx isomerů) xxxx xxxxxxxx, x xxxxxxxx derivátů imidazoiu x xxxxxxx xxxxxx xxxxxxxx použití a xxxxxxxxxxx zahrnutých xx Xxxxxxxxxxxxxx xxxxxxxx xxx xxx 2012*.
Xxxxxxxxxxx xxxxxxxx:
(x) Nespecifická xxxxxxxxxxx:
Xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxx, benzfetamin, benzylpiperazin, xxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxx, xxxxxxxxxxx, fendimetrazin, fenetylin, xxxxxxxxxxx, xxxxxxxx, fenmetrazin, xxxxxxxxxxx, fentermin, 4-xxxxxxxxxxxxxx (xxxxxxxx), xxxxxxxxxx, klobenzorex, xxxxxx, xxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, xxxxxxxxxxxx (x-), xxxxxxxxxxxxxxxxxxxxxx, xxxxxxxxxxxxxxxxxxxxxxxxx, xxxxxxxx, modafinil, norfenfluramin, x-xxxxxxxxxxxxxxx, xxxxxxxxxx, prolintan.
Xxxxxxxxxxxx, xxxxx xxxx xxxxxxxx xxxxxxx x xxxxx xxxxxxxx, je Xxxxxxxxxxx xxxxxx.
(b) Xxxxxxxxxx xxxxxxxxxxx (xxxxxxxx):
Xxxxxxxxx**, katin***, xxxxxxx****, xxxxxxxx, xxxxxxxxx, fenbutrazát, xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxx, levmetamfetamin, xxxxxxxxxxxx, xxxxxxxxxxxx****, xxxxxxxxxxxxx, xxxxxxxxxxxxxxx (xxxxxxxxxxxxxxxxx), niketamid, xxxxxxxxxxx, xxxxxxxxx, xxxxxxxxx, xxxxxxxxxxxxxxxxxxxx, xxxxxxx, xxxxxxxxxxx, propylhexedrin, xxxxxxxxxxxxx*****xxxxxxxxx, sibutramin, xxxxxxxxx, xxxxxxxxxxxxx a xxxxx xxxxx s xxxxxxxx xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxxx xxxxxxxxxxxx xxxxxx.
* Xxxxxxxxxxx látky xxxxxxxx do Xxxxxxxxxxxxxx xxxxxxxx 2012 (xxxxxxxxx, xxxxxxxxxx, xxxxxxxxxxxxxxxxx, xxxxxx, xxxxxxx, xxxxxxxxx, xxxxxxxx) xxxxxx považovány xx Xxxxxxxx xxxxx.
** Xxxxxxx podání xxxxxxxxxx (xxxx. xxxxx, xxxx xxxxxxxx) xxxx jeho xxxxxx xxxxxxxx x xxxxxxxxx xxxxxxxxxx xxxx xxxxxxxx.
*** Xxxxx xx zakázaný xxxxx xxx xxxxxxxxxxx xxxxx xxx 5 xxxxxxxxxx x 1 xx xxxx.
**** Xxxxxxx x methylefedrin xxxx xxxxxxxx xxx xxxxxxxxxxx xxxxx xxx 10 xxxxxxxxxx v 1 xx xxxx.
***** Xxxxxxxxxxxxx xx xxxxxxx, xxxxx xxxx xxxxxxxxxxx x moči xx xxxxx xxx 150 xxxxxxxxxx xx mililitr
X7. XXXXXXXXX
Xxxxxxxx xx xxxxxxxxxxx:
Xxxxxxxxxxx, xxxxxxxxxxxxx, xxxxxxxxx(xxxxxx), xxxxxxxx x xxxx deriváty, xxxxxxxxxxx, xxxxxxx, xxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx.
X8. XXXXXXXXXXX
Xxxxxxxx (xxxx. xxxxx, xxxxxx a xxxxxxxxx) xxxx syntetický delta9tetrahydrokanabinol (XXX) a xxxxxxxxxxxxxx (xxxx. "Xxxxx" /xxxxxxxxxx XXX018, XXX073/ a XX-210) jsou xxxxxxxx.
X9. XXXXXXXXXXXXXXXXXXXX
Xxxxxxx xxxxxxxxxxxxxxxxxxxx xxxxxxxx orálně, xxxxxxxx, xxxxxxxxxx nebo xxxxxxxxxxxxx xxxxxxxx xxxx xxxxxxxx.
XXXXX XXXXXXXX X URČITÝCH XXXXXXXX |
X1. XXXXXXX
Xxxxxxx (etanol) xx zakázaný pouze Xxx Xxxxxxx x xxxxxxxxxxxxx xxxxxxxx. Xxxxxxx xx xxxx xxxxxxxx xxxxxxxx xxxxxxxx x/xxxx xxxxxxxx xxxx. Prahová xxxxxxx xxx porušeni xxxxxxxxxxx xxxxxxxx (xxxxxxxxxxxxx xxxxxxx) je 0.10 x/x.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxx (WKF)
∙ Xxxxxxx sporty x xxxxxxxxxxxx(XXX)
∙ Xxxxxxxxxxx (XXXX)
∙ Xxxxxxxxxxx xxxxx (XXX)
∙ Xxxxx xxxxxxxxxx (XXX)
X2. XXXX-XXXXXXXXX
Xxxxx xxxx xxxxx xxxxxx, xxxx-xxxxxxxxx xxxx xxxxxxxx xxxxx Při Xxxxxxx x následujících xxxxxxxx.
∙ Xxxxxxxxxxxx xxxxx (XXX)
∙ Xxxxxxxx (xxxxxxx xxxxxxxxxx) (XXXX)
∙ Xxxxx (XXX)
∙ Xxxx (XXX)
∙ Kuželky x xxxxxxx (XXX)
∙ Xxxxxxx sporty a xxxxxxxxxxxx (XXX)
∙ Xxxxxxxxxxx (XXXX, XXX) (xxxxxxxx také Xxxx xxxxxx)
∙ Xxxxxxxx (XXX) - skoky xx lyžích x xxxxxxxxxxx xxxxxxxx-xxxxx a X-xxxxx,x xxxxxxxxx X-xxxxx x "xxx xxx"
∙ Petanque a xxxxxxx xxxxxx (CMSB)
∙ Střelba (XXXX, XXX) (xxxxxxxx xxxx Xxxx soutěž)
∙ Xxxxx (WDF)
∙ Xxxxx xxxxxxxxxx (XxX)
Xxxx-xxxxxxxxx xxxxxxxx xxxxxxxxxxx xxxxx:
Xxxxxxxxxx, xxxxxxxxxx, xxxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxx, celiprolol, xxxxxxx, xxxxxxxxx, xxxxxxxxxx, xxxxxxxxx, xxxxxxxxxxx, metipranolol, metoprolol, xxxxxxx, oxprenolol, xxxxxxxx, xxxxxxxxxxx, xxxxxxx, timolol, xxx ne x xxxxxxxx xxxxx na xx.
Xxxxxxxxx
Xxxxxx xxxxxxx č. 97/2012 Xx. x. x. xxxxx xxxxxxxxx xxxx 25.12.2012.
Xxxxxx xxxxxxx x. 97/2012 Xx. x. x. xxx xxxxxx xxxxxxx předpisem č. 98/2013 Sb. m. s. x účinností od 20.12.2013.
Xxxxx xxxxxxxxxxxx xxxxxxxx xxxxx xxxxxx xxxxxxxx xxxxxxxx x xxxxxxxx xxxx xxxxxxxxxxxxx, xxxxx xx xxxx xxxxxx derogační xxxxx shora xxxxxxxxx xxxxxxxx předpisu.